These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 18330028)

  • 1. [Anemia in patients with cancer].
    Kobune M; Kato J; Niitsu Y
    Nihon Rinsho; 2008 Mar; 66(3):524-9. PubMed ID: 18330028
    [TBL] [Abstract][Full Text] [Related]  

  • 2. September 2007 update on EORTC guidelines and anemia management with erythropoiesis-stimulating agents.
    Aapro MS; Link H
    Oncologist; 2008; 13 Suppl 3():33-6. PubMed ID: 18458123
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Erythropoiesis-stimulating agents for anemic patients with cancer.
    Sheikh S; Littlewood TJ
    Expert Rev Hematol; 2010 Dec; 3(6):697-704. PubMed ID: 21091146
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of recombinant erythropoietin in childhood cancer.
    Shankar AG
    Oncologist; 2008 Feb; 13(2):157-66. PubMed ID: 18305061
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Erythropoietin and chronic lymphocytic leukemia.
    Mauro FR; Gentile M; Foa R
    Rev Clin Exp Hematol; 2002; Suppl 1():21-31. PubMed ID: 12735212
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of epoetin in the management of anaemia in patients with lung cancer.
    Morère JF
    Lung Cancer; 2004 Nov; 46(2):149-56. PubMed ID: 15474662
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Erythropoiesis-stimulating agents: favorable safety profile when used as indicated.
    Nowrousian MR; Dunst J; Vaupel P
    Strahlenther Onkol; 2008 Mar; 184(3):121-36. PubMed ID: 18330508
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prediction of response to optimize outcome of treatment with erythropoietin.
    Beguin Y
    Semin Oncol; 1998 Jun; 25(3 Suppl 7):27-34. PubMed ID: 9671327
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment options for anemia, taking risks into consideration: erythropoiesis-stimulating agents versus transfusions.
    Spano JP; Khayat D
    Oncologist; 2008; 13 Suppl 3():27-32. PubMed ID: 18458122
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 2008 Japanese Society for Dialysis Therapy: guidelines for renal anemia in chronic kidney disease.
    Tsubakihara Y; Nishi S; Akiba T; Hirakata H; Iseki K; Kubota M; Kuriyama S; Komatsu Y; Suzuki M; Nakai S; Hattori M; Babazono T; Hiramatsu M; Yamamoto H; Bessho M; Akizawa T
    Ther Apher Dial; 2010 Jun; 14(3):240-75. PubMed ID: 20609178
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel erythropoiesis-stimulating agents: a new era in anemia management.
    Macdougall IC
    Clin J Am Soc Nephrol; 2008 Jan; 3(1):200-7. PubMed ID: 18077782
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Iron deficiency and anemia in oncology].
    Scotté F; Launay-Vacher V; Ray-Coquard I
    Bull Cancer; 2012 May; 99(5):563-70. PubMed ID: 22516641
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Erythropoietin in cancer patients.
    Glaspy JA
    Annu Rev Med; 2009; 60():181-92. PubMed ID: 18980468
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mechanisms of anaemia in patients with malignancy: implications for the clinical use of recombinant human erythropoietin.
    Cazzola M
    Med Oncol; 2000 Nov; 17 Suppl 1():S11-6. PubMed ID: 11188780
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Iron supplementation and erythropoiesis-stimulatory agents in the treatment of cancer anemia.
    Pedrazzoli P; Rosti G; Secondino S; Siena S
    Cancer; 2009 Mar; 115(6):1169-73. PubMed ID: 19152436
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of cancer-related anemia on clinical and quality-of-life outcomes.
    Gillespie TW
    Clin J Oncol Nurs; 2002; 6(4):206-11. PubMed ID: 12087616
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Erythropoietin: high profile, high scrutiny.
    Crawford J
    J Clin Oncol; 2007 Mar; 25(9):1021-3. PubMed ID: 17312331
    [No Abstract]   [Full Text] [Related]  

  • 18. Risks and benefits of erythropoiesis-stimulating agents in cancer management.
    Beutel G; Ganser A
    Semin Hematol; 2007 Jul; 44(3):157-65. PubMed ID: 17631180
    [TBL] [Abstract][Full Text] [Related]  

  • 19. EPO in cancer anemia: benefits and potential risks.
    Milano M; Schneider M
    Crit Rev Oncol Hematol; 2007 May; 62(2):119-25. PubMed ID: 17197190
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety update on erythropoiesis-stimulating agents: trials within and outside the accepted indications.
    Gascón P
    Oncologist; 2008; 13 Suppl 3():4-10. PubMed ID: 18458118
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.